WHWK today
$3.10-$0.14 (-4.32%)close Nov 12, 2026Trend
DailyDowntrend (starting)
4 hourBullish
1 hourExpanding
15 minLeaning Bearish
5 minStrong Bullish
Daily trend turns up above $5.50
Key levels
Resistance$3.51
Resistance$3.15
Support$2.91
Support$2.63
Latest news & SEC filings
EarningsWhitehawk Therapeutics posts quarterly loss of $0.23 per share, wider than $0.21 expected
SEC FilingWhitehawk Therapeutics, Inc. filed a report on a major company event (Form 8-K)
All WHWK news →About Whitehawk Therapeutics
Whitehawk Therapeutics is a clinical-stage oncology company developing antibody drug conjugates (ADCs) for cancer treatment. Its pipeline includes three next-generation ADC candidates, HWK-007, HWK-016, and HWK-206, which target tumor antigens PTK7, MUC16, and SEZ6, respectively, using a linker-payload platform that delivers a Topoisomerase I inhibitor. The company is based in the United States and holds global rights to develop and sell these therapies.
Based on the company's 10-K filed Mar 12, 2026.
Nasdaq · Healthcare
Whitehawk Therapeutics, Inc. (WHWK)
What Is the Price Target for WHWK?
SEPT Low Target
$8.00
SEPT Mid Target
$8.50
SEPT High Target
$9.00
Analyst Consensus
$8.50
Is WHWK a Buy or Sell Right Now?
Thesis
- •Revenue growing -72.5% YoY with DECLINING trend — consistent growth.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for WHWK.
Start Free Trial →Is WHWK Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$7.73
12
Moat Score
NONE
3/9
Piotroski Score
3.1
Altman Z-Score
What Is Smart Money Doing with WHWK?
Insider Signal
SELLING
0 buys / 14 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Lennon David James | director officer | Buy | 51,021 | $200K | May 14, 2026 |
| Dugan Margaret | officer | Buy | 19,132 | $75K | May 14, 2026 |
| BALL BRYAN | officer | Buy | 51,020 | $200K | May 14, 2026 |
| Giacobello Scott M. | officer | Buy | 38,265 | $150K | May 14, 2026 |
| Castelein Caley | director | Buy | 255,102 | $1000K | May 14, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →WHWK Growth Story
Revenue YoY
-72.5%
3yr Revenue CAGR
-22.3%
EPS Growth YoY
86.02%
FCF Growth YoY
-60.1%
Revenue Trend
DECLINING
Dark Pool Trades for WHWK
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for WHWK, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 20:54:19 | $3.20 | 22,441 | $$72K | SELL |
| 20:53:12 | $3.20 | 100,000 | $$320K | BUY |
| 20:46:38 | $3.20 | 24,063 | $$77K | BUY |
| 19:53:49 | $3.20 | 31,277 | $$100K | SELL |
| 19:41:06 | $3.19 | 4,600 | $$15K | BUY |
5 dark pool trades shown · $$584K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Whitehawk Therapeutics, Inc. (WHWK) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →WHWK — frequently asked questions
What is WHWK stock price today?
Whitehawk Therapeutics, Inc. (WHWK) is at $3.10, down 4.32% (-$0.14) at the Nov 12, 2026 close.
Why is WHWK stock moving today?
Latest WHWK news — Nov 9, 2026: Whitehawk Therapeutics posts quarterly loss of $0.23 per share, wider than $0.21 expected · Nov 9, 2026: Whitehawk Therapeutics, Inc. filed a report on a major company event (Form 8-K)
What is the WHWK price target?
The average analyst price target for WHWK is $8.50, ranging from $8 to $9, based on 4 analysts. Latest: Stifel initiates on Oct 1, 2026.
What do analysts rate WHWK?
Analyst ratings for WHWK: 0 Buy, 4 Hold, 0 Sell — consensus Hold.
Did WHWK beat earnings?
WHWK last reported on Aug 6, 2026: EPS -$0.20 vs -$0.30 expected — a beat of 32.4%.
Does WHWK pay a dividend?
WHWK does not currently pay a dividend.
What are WHWK support and resistance levels?
Support: $2.91, $2.63, $2.36. Resistance: $3.15, $3.51, $3.73.
What are insiders doing with WHWK?
Insider activity: SELLING, 0 buys and 14 sells in the last 90 days.
What is the latest news on WHWK?
Nov 9, 2026: Whitehawk Therapeutics posts quarterly loss of $0.23 per share, wider than $0.21 expected · Nov 9, 2026: Whitehawk Therapeutics, Inc. filed a report on a major company event (Form 8-K)